Post Marketing Information DHCPL 18/03/2019 Benlysta (belimumab) and risk of serious depression and/or suicidal ideation or behaviour or self-injury DHCPL 11/02/2014 Two Post-Marketing Reports of Progressive Multifocal Leukoencephalopathy (PML) in Patients with Systemic Lupus Erythematosus (SLE) treated with Benlysta® (belimumab) DHCPL 09/01/2013 Hypersensitivity and infusion reactions related to Benlysta™ (Belimumab)
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Benlysta Injection, Powder, Lyophilized, For Solution 120 mg/vial National University Hospital Benlysta Injection, Powder, Lyophilized, For Solution 400 mg/vial National University Hospital